@article{b301bcad5eb24237b31eefd837ae1a15,
title = "Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites",
abstract = "Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.",
keywords = "Bronchopulmonary dysplasia, NO CLD trial, Nitrite",
author = "Posencheg, {M. A.} and Gow, {A. J.} and Truog, {W. E.} and Ballard, {R. A.} and A. Cnaan and Golombek, {S. G.} and Ballard, {P. L.}",
note = "Funding Information: We thank the nurses, respiratory therapists, and physicians at participating hospitals, the NO CLD study coordinators, S Wadlinger and C Coburn, the families and infants who participated in this study, Y Ning, T McDevitt, M Norberg, and C Castor for technical assistance, H Ischiropoulos for assistance with specimen analysis, S Lorch and M Segal for statistical assistance, L Parton and J Merrill for patient recruitment, and IKARIA for providing study equipment and gas. This investigation was supported by grants from the National Institutes of Health: #U01 HL62514; P50 HL56401; P30 HD26979; MRDDRC P30 HD26979; R01 HL70560, HL62472, HL62868, HL75930, and HL 73896; and from General Clinical Research Centers Program: M01 RR00240; M01 RR00084; M01 RR00425; M01 RR001271; M01 RR00064; and M01 RR00080. Funding Information: RAB and PLB have received research grant support and advisor fees from IKARIA (formerly INO Therapeutics). SGG has received speaker{\textquoteright}s fees from IKARIA. IKARIA provided study gas and masked delivery systems for the primary NO CLD trial, but did not financially support or have a role in the design, analysis, interpretation, or reporting of this study. MAP wrote the first draft of the paper.",
year = "2010",
month = apr,
doi = "10.1038/jp.2009.155",
language = "English (US)",
volume = "30",
pages = "275--280",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "4",
}